Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 106
Filter
1.
J. bras. med ; 97(3): 36-39, nov.-dez. 2009. tab
Article in Portuguese | LILACS | ID: lil-539052

ABSTRACT

A doença do refluxo gastroesofagiano (DRGE) é uma afecção crônica frequente na prática médica, interferindo negativamente na qualidade de vida dos pacientes. Apresenta um amplo espectro de sintomas, classificados como típicos e atípicos, sendo a pirose a principal manifestação. O tratamento inclui medidas não farmacológicas e farmacológicas.


Gastroesophagel reflux disease is a frequent cronical condition in the medical practice that adversely affects patient´s life quality. Is has a wide spread of symptoms, classified as typical and antypical. Hearburn is the main symptom. The treatment includes non-pharmacological and pharmacological measures.


Subject(s)
Male , Female , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/physiopathology , Gastroesophageal Reflux/therapy , Cimetidine/therapeutic use , Omeprazole/therapeutic use , Deglutition Disorders/complications , Deglutition Disorders/diagnosis
2.
An. bras. dermatol ; 84(1): 23-29, jan.-fev. 2009. ilus, tab
Article in Portuguese | LILACS | ID: lil-511460

ABSTRACT

FUNDAMENTOS: Verrugas são proliferações epiteliais na pele e mucosas causadas por diversos tipos de HPV. Elas podem involuir espontaneamente ou aumentar em número e tamanho de acordo com estado imunitário do paciente. A cimetidina e o sulfato de zinco têm importante efeito no sistema imune, sendo usados como imunomoduladores no tratamento de diversas doenças. OBJETIVO:Comparar a eficácia terapêutica de cimetidina e sulfato de zinco no tratamento de verrugas cutâneas de difícil tratamento. MÉTODOS: Estudo prospectivo duplo-cego randomizado. Dezoito pacientes com verrugas múltiplas foram divididos em dois grupos, um recebeu cimetidina 35mg/kg/dia (máximo 1.200mg/dia), e o outro, sulfato de zinco 10mg/kg/dia (máximo de 600mg/dia) por três meses. RESULTADOS: Dos 18 pacientes do estudo, nove receberam cimetidina, e nove, sulfato de zinco; apenas um do grupo do sulfato de zinco não completou o tratamento devido a náuseas e vômitos. Cura foi obtida em cinco pacientes tratados com sulfato de zinco, e apenas um não obteve alteração das lesões. Do grupo da cimetidina cinco não apresentaram modificação, e quatro apresentaram diminuição inferior a 30% das lesões iniciais. CONCLUSÕES: Sulfato de zinco na dose de 10mg/kg/dia parece ser mais efetivo que cimetidina para o tratamento de crianças e adultos com verrugas múltiplas e de difícil manejo. A pequena casuística deste trabalho não permite, entretanto, conclusão categórica.


Background: Warts are epithelial proliferations on the skin and mucous membrane caused by various types of HPV. They can decrease spontaneously or increase in number and size according to patient's immune status. Cimetidine and zinc sulphate have important effects on the immune system and are used as immunomodulators in the treatment of various diseases. Objective: To compare the efficacy of cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts. Methods: A random double-blind prospective study. Eighteen patients with multiple warts were divided into two groups: one took 35mg/Kg/day of cimetidine (maximum 1200 mg/day) and the other 10 mg/Kg/day of zinc sulphate (maximum 600 mg/day) for three months. Results: Among the 18 patients who participated in the study, nine took cimetidine and nine zinc sulphate. Just one patient in the zinc sulphate group did not complete treatment due to nausea and vomiting. Five patients who were treated with zinc sulphate were cured and only one did not show modifications in lesions. Among the group who was treated with cimetidine, five did not show modifications in lesions and four showed decrease from baseline below 30%. Conclusions: 10 mg/Kg/day zinc sulphate dose seems to be more effective than cimetidine for the treatment of children and adults with multiple and difficult-to-handle warts. However, the small number of patients did not enable any definitive conclusion.


Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Young Adult , Cimetidine/therapeutic use , /therapeutic use , Warts/drug therapy , Zinc Sulfate/therapeutic use , Double-Blind Method , Prospective Studies , Warts/pathology , Young Adult
4.
Rev. chil. pediatr ; 70(5): 415-22, oct. 1999. ilus
Article in Spanish | LILACS | ID: lil-263498

ABSTRACT

La panencefalitis esclerosante subaguda postsarampión (PEES) es en la actualidad una entidad infrecuente en aquellos países donde existen programas regulares de vacunación contra el sarampión. Presentamos un caso, con evolución rápida a la muerte, en el cual fueron observados hallazgos característicos. Entre los más relevantes: títulos elevados de anticuerpos antisarampión en el líquido cefalorraquídeo (LCR), patrón periódico en el EEG, fenómenos de desmielinización progresiva en el scanner y resonancia nuclear magnética cerebral, asociados a la presencia constante de crisis mioclónicas. A pesar de una terapia continua con alfa-interferón intratecal, cimetidina en dosis inmunorreguladoras y con antiviral, se observó un deterioro progresivo del paciente. El estudio neuropatológico reveló compromiso a nivel de los centros semiovales de los hemisferios frontales, de predominio izquierdo


Subject(s)
Humans , Male , Child , Measles/complications , Subacute Sclerosing Panencephalitis/etiology , Cimetidine/therapeutic use , Interferon-alpha/therapeutic use , Subacute Sclerosing Panencephalitis/diagnosis , Subacute Sclerosing Panencephalitis/drug therapy
5.
Rev. imagem ; 21(1): 7-13, jan.-mar. 1999. tab
Article in Portuguese | LILACS | ID: lil-259932

ABSTRACT

Objetivo - Avaliar as decisöes tomadas por radiologistas em relaçäo à escolha do tipo de meio de contraste intravenoso (agente näo-iônico versus agente iônico convencional) e a freqüência do uso de esquemas profiláticos. Material e métodos - Um questionário, baseado em estudo publicado na literatura internacional, foi aplicado durante a 27ª Jornada Paulista de Radiologia, 1997. Foram coletados 432 questionários, sendo aproveitados para o estudo 187 (43 por cento). Resultados - A maioria dos radiologistas utiliza meio de contraste näo-iônico de forma seletiva. A profilaxia com corticosteróides e anti-histamínicos em pacientes com risco de reaçöes adversas é usada com freqüência similar, tanto nos casos de uso seletivo ou universal de meio de contraste näo-iônico. Há grande diversidade dos esquemas de pré-medicaçäo (tipo de droga usada e posologia), sendo que os anti-histamínicos, apesar de bastante usados em associaçäo com corticosteróides, säo raramente utilizados de forma isolada. Conclusäo - O meio de contraste näo-iônico é usado seletivamente pela maioria dos radiologistas que escolhem este tipo de contraste em pacientes que consideram com risco de reaçöes adversas. Os esquemas de pré-medicaçäo säo amplamente utilizados, havendo grande heterogeneidade quanto ao tipo de esquema utilizado para cada situaçäo clínica proposta


Subject(s)
Humans , Contrast Media/adverse effects , Premedication/standards , Surveys and Questionnaires , Radiography/standards , Adrenal Cortex Hormones/therapeutic use , Brazil , Cimetidine/therapeutic use , Contrast Media/administration & dosage , Contrast Media/classification , Histamine H1 Antagonists/therapeutic use , Histamine H2 Antagonists/therapeutic use , Iodine Compounds , Iodine Compounds/adverse effects
7.
Rev. argent. cir ; 73(3/4): 82-7, sept.-oct. 1997. ilus
Article in Spanish | LILACS | ID: lil-207980

ABSTRACT

La Hemorragia digestiva alta (HDA) en pacientes trasplantados renales constituye un cuadro de gravedad no solo por poner en riesgo la vida del paciente, sino la funcionalidad del injerto. Se han documentado cuatro casos (1,2 por ciento) de HDA en pacientes trasplantados renales con riñon funcionante sobre un total de 340 trasplantes en 328 pacientes desde el advenimiento de la ciclosporina como droga inmunosupresora en el país en enero de 1986 hasta el 11 de abril de 1996. No hubo defunciones ni pérdidas del injerto directamente vinculadas a la HDA. La baja incidencia de HDA estaria relacionada a la profilaxis perioperatoria con bloqueantes H2 y a la rigurosa selección de los receptores. La cirugía profiláctica pre trasplante no está indicada. El tratamiento quirúrgico esta indicado en los casos refractarios a la terapéutica médica. El adecuado tratamiento y profilaxis de cualquier patología causante de una potencial HDA, especialmente la enfermedad ulceropéptica, y la selección de los pacientes receptores aseguran un trasplante renal con muy baja incidencia de complicaciones hemorrágicas esofagogastroduodenales


Subject(s)
Humans , Male , Adult , Middle Aged , Cyclosporine/therapeutic use , Gastrointestinal Hemorrhage/etiology , Kidney Transplantation/adverse effects , Peptic Ulcer Hemorrhage/physiopathology , Cimetidine/adverse effects , Cimetidine/therapeutic use , Cyclosporine/adverse effects , Cytomegalovirus Infections/complications , Cytomegalovirus/pathogenicity , Gastrointestinal Hemorrhage , Gastrointestinal Hemorrhage/mortality , Helicobacter pylori/pathogenicity , Immunosuppression Therapy/adverse effects , Muromonab-CD3/therapeutic use , Ranitidine/adverse effects , Ranitidine/therapeutic use , Retrospective Studies , Peptic Ulcer Hemorrhage/etiology , Peptic Ulcer Hemorrhage/drug therapy , Peptic Ulcer/etiology , Peptic Ulcer/physiopathology
8.
Arch. argent. dermatol ; 47(4): 161-6, jul.-ago. 1997. ilus
Article in Spanish | LILACS | ID: lil-204989

ABSTRACT

La fasceítis eosinofílica es un cuadro clínico de curso benigno que aparece en general tras un esfuerzo físico importante. Se presenta un paciente de 60 años, sexo masculino, con una fasceítis eosinofílica de extenso compromiso cutáneo, polineuropatía y mucinosis papulosa, con buena respuesta al tratamiento combinado con corticoides y cimetidina


Subject(s)
Humans , Male , Middle Aged , Autoimmune Diseases/complications , Eosinophilia/complications , Fasciitis/diagnosis , Cimetidine/therapeutic use , Diagnosis, Differential , Eosinophilia/blood , Eosinophilia/pathology , Fasciitis/drug therapy , Fasciitis/immunology , Methylprednisolone/therapeutic use , Neuritis/complications , Neuritis/diagnosis , Neuritis/physiopathology
10.
Indian J Exp Biol ; 1996 Jul; 34(7): 683-8
Article in English | IMSEAR | ID: sea-62763

ABSTRACT

Effect of UL-409, a multiconstituent herbal preparation was evaluated on different models of gastric ulcers in rats. In doses 25, 50 and 100 mg/kg. p.o. it significantly reduced the gastric secretory volume and ulcer index in pylorus ligated rats, and showed significant mucoprotective effect at 100 mg/kg dose on both acute and chronic treatment. UL-409(50 and 100 mg/kg doses) prevented immobilization induced gastric ulceration and showed significant mucosal protection. In forced swimming induced ulcers, UL-4093(50 and 100 mg/kg) completely abolished the ulcerogenesis and strengthened the mucosal barrier. It also protected the indomethacin-induced gastric ulcers and significantly increased the mucosal content. Cimetidine (10 mg/kg) and diazepam (20 mg/kg) were used for comparison. The results indicate that UL-409 has anti-ulcerogenic effects due to its mucoprotective effect. The preparation can be used alone or in combination with other ulcer healing agents.


Subject(s)
Animals , Anti-Ulcer Agents/therapeutic use , Cimetidine/therapeutic use , Female , Male , Medicine, Ayurvedic , Plant Extracts/therapeutic use , Rats , Rats, Inbred Strains , Stomach Ulcer/drug therapy
11.
Arch. med. res ; 27(1): 15-8, 1996. tab
Article in English | LILACS | ID: lil-200284

ABSTRACT

In this study, cimetidine was used to treat patients with hemophilia A and inhibitors to factor VIII who presented with acute hemorrhages (Group A) and those without hemorrahges (Group B). The dose of cimetidine was 15 mg/kg/day. Group A consisted of five patients with inhibitors between 156 and > 10,000 Bethesda Units (BU), all with serious hemorrhagic problems. The control of hemorrhaging was effective in 100 per cent of these patients, although inhibitor levels remained high (25-380 BU). Group B consisted of seven patients who did not have hemorrhages, whose inhibitor levels were 41-358 BU. Five of these patients no longer had anamnestic responses to Factor VIII after several months of treatment with cimetidine. No difference in the response to cimetidine was seen between HIV positive and HIV negative patients. The results suggest that cimetidine is useful to suppress inhibitores to Factor VIII in patients with hemophilia A


Subject(s)
Adolescent , Adult , Humans , Male , Female , Antiviral Agents , Cimetidine/therapeutic use , Factor IX/physiology , Factor VIII/antagonists & inhibitors , Hemophilia A/therapy , Hemorrhage/physiopathology , Interleukin-2/physiology , Ranitidine/therapeutic use , Thromboplastin/physiology
14.
Article in English | IMSEAR | ID: sea-38947

ABSTRACT

104 duodenal ulcer patients were classified into non-smokers (76) and smokers (28). Their age range was between 14-72 years. They were randomly treated with cimetidine (28 non-smokers and 8 smokers), colloidal bismuth (27 non-smokers and 10 smokers) and sucralfate (21 non-smokers and 10 smokers). Follow-up endoscopic examination at 4, 6 and 8 weeks showed that overall healing rates were better in the non-smokers than in the smokers (64.5% against 46.4% at 4 weeks and 92.1% against 67.8% at 6 weeks) and almost all ulcers had healed at the end of 8 weeks (100% in non-smokers and 96.4% in smokers). Among non-smokers, there were no statistically significant differences in the healing rates by any medication at any period of time. Among smokers, colloidal bismuth had significant better healing rate at 6 weeks over cimetidine and sucralfate. (p = 0.04 and p = 0.041 respectively). Overall relapse rates were higher among smokers (32.1%) than non-smokers (10.5%). Of the 3 medications, sucralfate had the lowest relapse rate in both smokers (20%) and non-smokers (9.5%), while colloidal bismuth had the highest relapse rates (40% for smokers and 11.1% for non-smokers).


Subject(s)
Adolescent , Adult , Aged , Bismuth/therapeutic use , Cimetidine/therapeutic use , Colloids , Duodenal Ulcer/drug therapy , Female , Humans , Male , Middle Aged , Recurrence , Smoking , Sucralfate/therapeutic use , Treatment Outcome
15.
Asian Pac J Allergy Immunol ; 1994 Jun; 12(1): 51-8
Article in English | IMSEAR | ID: sea-37179

ABSTRACT

In a double-blind placebo-control study the immunomodulating effect of cimetidine treatment for one week and placebo was investigated for cell-mediated immune reactions of 22 patients with herpes zoster (HZ). The mitogen induced leukocyte migration inhibition test (LMIT) and the in vitro proliferation of the patients' lymphocytes to exogenous IL-2 were used. Before any treatment, the mitogen induced leukocyte migration inhibition capacity (LMIC) of HZ patients was found to be significantly reduced (p < 0.02) as compared to healthy blood bank donors (controls). After one week, within the same treatment, the LMIC was significantly improved (p < 0.01). The patients' lymphoproliferative response to IL-2, before any treatment, was not significantly different from that of controls (p < 0.05). However, significantly higher values (p < 0.001) were found in patients tested 7 days after the disease onset as compared to those tested after 12 days. One-week cimetidine treatment significantly improved (p < 0.05) the lymphoproliferative response to IL-2 of initially low responders and had no effect on higher responder patients. In contrast to this, after one week of placebo treatment, a significant decrease in the patients' lymphoproliferative response to IL-2 could be observed as compared to patients' initial responses (p < 0.05) or to those of controls (p < 0.05). Although the number of cases is very small. The data suggest that after cimetidine treatment, as compared to placebo, healing from skin rash and pain was achieved in a significantly shorter time (p < 0.01).


Subject(s)
Adult , Aged , Aged, 80 and over , Case-Control Studies , Cell Migration Inhibition , Cimetidine/therapeutic use , Double-Blind Method , Female , Herpes Zoster/drug therapy , Humans , Immunity, Cellular/drug effects , Interleukin-2/immunology , Male , Middle Aged
16.
Dermatol. rev. mex ; 38(3): 202-3, mayo-jun. 1994.
Article in Spanish | LILACS | ID: lil-143270

ABSTRACT

Se reportan los casos de dos niños con verrugas vulgares diseminadas que respondieron favorablemente al tratamiento con cimetidina por vía bucal. La actividad inmunomoduladora de la cimetidina se ha sugerido como posible mecanismo de acción


Subject(s)
Humans , Male , Child , Cimetidine/administration & dosage , Cimetidine/therapeutic use , Warts/drug therapy
17.
Rev. argent. dermatol ; 75(2): 91-6, abr.-jun. 1994. ilus
Article in Spanish | LILACS | ID: lil-137098

ABSTRACT

Se presenta el estudio de 9 pacientes que padecen psoriasis con serologia positiva para HIV.Entre tres de ellos la aparicion de la psoriasis fue previa al dignostico del HIV+, en los restantes posterior. Las formas clinicas de psoriasis halladas fueron: vulgar en tres, invertida en tres, pustulosa en dos y con compromiso de pequeños pliegues en uno. Los antecedentes familiares de psoriasis estuvieron presentes en uno, no se consignaron en dos y estuvieron ausentes en seis. El estadio clinico de la infeccion por HIV fue C3 en cinco, B2 en tres y en uno B3. La psoriasis se caracterizo por ser mas severa y, en dos casos, acompañada de sepsis estafilococcica. El tratamiento con medidas locales(cremas con corticoides, queratoliticos y balneoterapia) obtuvo resultados variables y la antibioticoterapia endovenosa instituida por la sepsis mejoro notablemente las lesiones cutaneas.


Subject(s)
Humans , Male , Female , Adult , Psoriasis/therapy , Acquired Immunodeficiency Syndrome/therapy , Adrenal Cortex Hormones/therapeutic use , Balneology , Cimetidine/therapeutic use , Hydroxyurea/administration & dosage , Hydroxyurea/adverse effects , Zidovudine/therapeutic use
18.
Folha méd ; 108(3): 49-52, mar. 1994. tab
Article in Portuguese | LILACS | ID: lil-154159

ABSTRACT

A presente experimentaçåo foi conduzida com o objetivo de se investigar a influência da administraçåo pós-operatória da somatostatina na regeneraçåo hepática de ratos submetidos à ressecçåo parcial do fígado. Vinte e três ratos divididos em três grupos foram utilizados nesta pesquisa: GRUPO I(Controle): hepatectomia e administraçåo subcutânea (SC) de soluçåo salina (1ml de 12/12 horas); GRUPO II(Somatostatina): hepatectomia e administraçåo SC de somatostatina (15 mg/Kg) de 12/12h; GRUPO III ("SHAM"): laparotomia, manipulaçåo do fígado sem ressecçåo e injeçöes de soluçåo salina SC (1 ml de 12/12 horas). Após 72 horas de observaçåo pós-operatória, os animais foram novamente anestesiados, submetidos a nova laparoscopia na qual o fígado residual foi retirado e processado para estudo histológico, onde se realizou a contagem do número de mitoses. As avaliaçöes histológicas demostraram um significativo aumento do número de mitoses no fígado dos animais que receberam a somatostina no pós-operatório quando comparado com os animais do grupo de controle. Os autores concluíram com base nos achados desta investigaçåo que a somatostina estimula o processo de regeneraçåo hepática em ratos submetidos à ressecçåo parcial do fígado


Subject(s)
Animals , Rats , Liver Regeneration , Somatostatin/therapeutic use , Cimetidine/therapeutic use , Liver/anatomy & histology , Hepatectomy , Ranitidine/therapeutic use , Rats, Inbred Strains/surgery , Somatostatin/pharmacology
19.
Article in English | IMSEAR | ID: sea-86924

ABSTRACT

A double blind randomised trial, comparing a new H2-receptor antagonist, Roxatidine acetate, with Cimetidine was carried out in 47 patients of uncomplicated, endoscopically proven duodenal ulcer. Twenty seven patients were treated with Roxatidine 75 mg twice daily and 20 patients were treated with Cimetidine 200 mg 3 times a day and 400 mg at bed time for 4 weeks. At the end of 4 weeks, total pain relief was obtained in 74% and 70% patients receiving Roxatidine and Cimetidine respectively. Complete endoscopic healing at the end of 4 weeks was observed in 92.3% patients receiving Roxatidine and 85% patients receiving Cimetidine. These differences were statistically not significant. No significant side effects were observed in either group. We conclude that Roxatidine acetate is comparable to cimetidine in relieving pain and endoscopic healing of duodenal ulcer and has an excellent safety profile.


Subject(s)
Cimetidine/therapeutic use , Double-Blind Method , Duodenal Ulcer/drug therapy , Female , Histamine H2 Antagonists/therapeutic use , Humans , Male , Piperidines/therapeutic use
20.
Arq. bras. med ; 67(4): 311-5, jul.-ago. 1993. tab
Article in Portuguese | LILACS | ID: lil-138211

ABSTRACT

Foram estudados 98 pacientes com úlcera péptica duodenal distribuídos de forma randômica em dois grupos. Um grupo recebeu antiácido liquido de alta potência (282,4mEq/dia) dividido em 4 tomadas durante 4 semanas e outro recebeu cimetidina (800 mg/dia) dividida em 2 tomadas por igual período. A potência antiácida da associaçäo líquida utilizada é de 7,06 mEq/ml. Todos os pacientes foram avaliados clinicamente no pré-tratamento e duas e quatro semanas após, com exames endoscópicos realizados na admissäo e após quatro semanas. A eficácia, considerada como cicatrizaçäo da úlcera duodenal associada a melhora da sintomatologia foi equivalente para ambos os tratamentos, näo havendo diferença estatisticamente significante. A tolerabilidade de ambas as drogas foi considerada boa


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Antacids/therapeutic use , Cimetidine/therapeutic use , Duodenal Ulcer/drug therapy , Peptic Ulcer/drug therapy , Cimetidine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL